{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-007303","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.974254+00:00","generated_at":"2026-05-27T22:22:15.166015+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Revelation starts Phase 1b Gemini CKD study; shareholders approve reverse split but reincorporation fails","bullets":["PRIME Phase 1b study of Gemini in Stage 3-4 CKD patients started; dosing mid-Feb, topline data expected mid-year.","Shareholders approved reverse stock split (range 1:2 to 1:50) with board discretion; 3.96M for, 163K against.","Change of domicile from Delaware to Nevada failed despite 97% of votes present in favor (2.96M for, 74K against) due to insufficient affirmative votes of outstanding shares.","Shareholders approved issuance of shares under warrants (Dec 2024) exceeding 20% threshold; also approved meeting adjournment.","1,089,301 broker non-votes affected the change-of-domicile and warrant issuance proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-007303","json":"https://secwatch.observer/filing/0000950170-25-007303.json","markdown":"https://secwatch.observer/filing/0000950170-25-007303.md","text":"https://secwatch.observer/filing/0000950170-25-007303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/0000950170-25-007303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/revb-20250117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:22:15.166015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}